183 related articles for article (PubMed ID: 26389969)
1. 'Deepness of Response' Is Associated with Overall Survival in Standard Systemic Chemotherapy for Metastatic Colorectal Cancer.
Nozawa H; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Hata K; Kazama S; Yamaguchi H; Ishihara S; Sunami E; Kitayama J; Watanabe T
Chemotherapy; 2014; 60(5-6):360-7. PubMed ID: 26389969
[TBL] [Abstract][Full Text] [Related]
2. Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
Tsuji A; Sunakawa Y; Ichikawa W; Nakamura M; Kochi M; Denda T; Yamaguchi T; Shimada K; Takagane A; Tani S; Kotaka M; Kuramochi H; Furushima K; Koike J; Yonemura Y; Takeuchi M; Fujii M; Nakajima T
Target Oncol; 2016 Dec; 11(6):799-806. PubMed ID: 27306648
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
[TBL] [Abstract][Full Text] [Related]
4. Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.
Froelich MF; Petersen EL; Heinemann V; Nörenberg D; Hesse N; Gesenhues AB; Modest DP; Sommer WH; Hofmann FO; Stintzing S; Holch JW
Clin Colorectal Cancer; 2020 Dec; 19(4):291-300.e5. PubMed ID: 32917529
[TBL] [Abstract][Full Text] [Related]
5. CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.
Sunakawa Y; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Ichikawa W
Target Oncol; 2017 Dec; 12(6):787-794. PubMed ID: 29064002
[TBL] [Abstract][Full Text] [Related]
6. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
7. Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer.
Pander J; van Huis-Tanja L; Böhringer S; van der Straaten T; Gelderblom H; Punt C; Guchelaar HJ
PLoS One; 2015; 10(7):e0131091. PubMed ID: 26222057
[TBL] [Abstract][Full Text] [Related]
8. Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab.
Osumi H; Matsusaka S; Suenaga M; Shinozaki E; Mizunuma N
Onco Targets Ther; 2015; 8():2005-13. PubMed ID: 26273206
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.
Bai L; Wang F; Li ZZ; Ren C; Zhang DS; Zhao Q; Lu YX; Wang DS; Ju HQ; Qiu MZ; Wang ZQ; Wang FH; Xu RH
Medicine (Baltimore); 2016 Dec; 95(51):e4531. PubMed ID: 28002313
[TBL] [Abstract][Full Text] [Related]
10. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
Heinemann V; Stintzing S; Modest DP; Giessen-Jung C; Michl M; Mansmann UR
Eur J Cancer; 2015 Sep; 51(14):1927-36. PubMed ID: 26188850
[TBL] [Abstract][Full Text] [Related]
11. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
Zhao Z; Pelletier E; Barber B; Bhosle M; Wang S; Gao S; Klingman D
Curr Med Res Opin; 2012 Feb; 28(2):221-9. PubMed ID: 22171947
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients.
De Stefano A; Carlomagno C; Pepe S; Bianco R; De Placido S
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1207-13. PubMed ID: 21409384
[TBL] [Abstract][Full Text] [Related]
13. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
14. First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study.
Liu S; Jiang C; Yang L; Huang J; Peng R; Wang X; He W; Bai L; Zhou Y; Zhang B; Xia L
Sci Rep; 2020 Jul; 10(1):12336. PubMed ID: 32704062
[TBL] [Abstract][Full Text] [Related]
15. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
[TBL] [Abstract][Full Text] [Related]
16. Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer.
Ito M; Kusaba H; Mukaide S; Kishimoto J; Shimokawa H; Tamura S; Makiyama A; Hirano G; Oda H; Shirakawa T; Komoda M; Uchino K; Tanaka R; Mitsugi K; Esaki T; Arita S; Ariyama H; Akashi K; Baba E
Anticancer Drugs; 2017 Nov; 28(10):1166-1173. PubMed ID: 28906258
[TBL] [Abstract][Full Text] [Related]
17. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment.
Odabas H; Ozdemir N; Isik M; Abali H; Oksuzoglu B; Kos T; Civelek B; Babacan AN; Dogan U; Zengin N
J BUON; 2011; 16(3):460-3. PubMed ID: 22006750
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ueno M; Yamaguchi T
Asia Pac J Clin Oncol; 2014 Dec; 10(4):322-9. PubMed ID: 23915091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
